Thymosin Alpha-1 (TA1): A Tracking Guide for an Approved Immune Peptide

Thymosin Alpha-1 (TA1) is one of the better-studied immune peptides. It is a 28-amino-acid peptide originally isolated from thymic tissue and now produced synthetically. As Zadaxin it is approved in 35-plus countries for chronic hepatitis B and C and used adjunctively in cancer and immune-compromised contexts. In some jurisdictions it is prescription, in others it is research-only — know your local rules.

What it does

TA1 modulates T-cell maturation and function, shifts cytokine balance, and has documented effects on dendritic cell activity. Clinical trial endpoints have included viral load reduction in hepatitis, response to vaccination in older adults, and adjunct outcomes in oncology. The mechanistic story is more concrete than for most "immune peptides."

Typical protocol shape

Reported patterns vary by indication:

• Hepatitis protocols in trials: 1.6 mg SC twice weekly for 6 to 12 months
• Self-experimenter immune-support cycles: shorter courses, often 4 to 8 weeks
• Pre- and post-illness courses around acute infection

Subcutaneous administration is standard. The peptide is short-acting; twice-weekly dosing reflects pharmacokinetics, not convenience.

What to track daily

• Dose, site, route, time
• Energy (1 to 10)
• Sleep quality and duration
• Any signs of infection or inflammation
• Mood
• Side effects (injection-site reactions are most commonly reported)

What to track weekly

• Resting heart rate, HRV
• Training recovery
• Frequency and severity of any minor illness
• Body weight as a general health marker

Bloodwork worth doing

If you have a clinical reason and access:

• CBC with differential
• CRP and ESR
• Lymphocyte subsets (CD4, CD8, NK cells) if your physician will order them
• Liver panel if you have any hepatic history
• Vitamin D

Baseline, then re-check at 8 to 12 weeks. TA1 effects on lymphocyte populations take time to show up.

Realistic expectations

TA1 is one of the few immune peptides with a real clinical evidence base, but the trial endpoints are slow (viral load over months, vaccine response over weeks). Day-to-day "I feel different" effects are mostly noise. If you are tracking for a specific outcome (fewer infections this winter, better post-illness recovery), give it months.

Common mistakes

• Running it for two weeks and quitting. The evidence base is built on multi-month protocols.
• Stacking with other immune peptides. You lose all ability to attribute effects.
• Skipping bloodwork. TA1 is one of the rare immune peptides where labs are actually informative — use them.
• Ignoring sleep, stress, and nutrition. These dominate immune function. A clean TA1 log on top of chronic sleep deprivation will not show much.

A tracking template

• Weeks minus 4 to 0: baseline daily metrics, baseline bloodwork
• Weeks 1 to 12: twice-weekly dosing, daily log
• Week 12: repeat bloodwork
• Weeks 13 to 24: off-cycle, continue daily tracking
• Review the whole window in Peptide IA

Safety notes

TA1 has a relatively benign side-effect profile in clinical trials, but it is a real immunomodulator. Discuss with a physician before starting, particularly if you have autoimmune disease, are on immunosuppressive therapy, or have a transplant history.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.